PRO17 Cost-Minimization Analysis of Lanreotide Autogel Versus Octreotide LAR in Patients with Acromegaly in the Brazilian Public Health System
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.1002
https://www.valueinhealthjournal.com/article/S1098-3015(21)01219-5/fulltext
Title :
PRO17 Cost-Minimization Analysis of Lanreotide Autogel Versus Octreotide LAR in Patients with Acromegaly in the Brazilian Public Health System
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01219-5&doi=10.1016/j.jval.2021.04.1002
First page :
Section Title :
Open access? :
No
Section Order :
10499